Global Antibody-drug Conjugates Market Growth 2023-2029

Global Antibody-drug Conjugates Market Growth 2023-2029

Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue.

LPI (LP Information)' newest research report, the “Antibody-drug Conjugates Industry Forecast” looks at past sales and reviews total world Antibody-drug Conjugates sales in 2022, providing a comprehensive analysis by region and market sector of projected Antibody-drug Conjugates sales for 2023 through 2029. With Antibody-drug Conjugates sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antibody-drug Conjugates industry.

This Insight Report provides a comprehensive analysis of the global Antibody-drug Conjugates landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antibody-drug Conjugates portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Antibody-drug Conjugates market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antibody-drug Conjugates and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antibody-drug Conjugates.

The global Antibody-drug Conjugates market size is projected to grow from US$ 2769.7 million in 2022 to US$ 3865.1 million in 2029; it is expected to grow at a CAGR of 3865.1 from 2023 to 2029.

North America is the largest market with about 59% market share. Europe is follower, accounting for about 27% market share.

The key players are ImmunoGen, Seattle Genetics, Roche, Takeda etc. Takeda is the largest manufacturer with about 57% revenue market share.

This report presents a comprehensive overview, market shares, and growth opportunities of Antibody-drug Conjugates market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Adcetris
Kadcyla

Segmentation by application
Breast Cancer
Lymphoma

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
ImmunoGen
Seattle Genetics
Roche
Takeda

Key Questions Addressed in this Report

What is the 10-year outlook for the global Antibody-drug Conjugates market?

What factors are driving Antibody-drug Conjugates market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Antibody-drug Conjugates market opportunities vary by end market size?

How does Antibody-drug Conjugates break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.